The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 09, 2016

Filed:

May. 31, 2013
Applicant:

The United States of America, As Represented BY the Secretary, Department of Health and Human Services, Bethesda, MD (US);

Inventors:

Mitchell Ho, Urbana, MD (US);

Yen T. Phung, Annandale, VA (US);

Wei Gao, Rockville, MD (US);

Yifan Zhang, Haymarket, VA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/30 (2006.01); A61K 39/395 (2006.01); G01N 33/68 (2006.01); A61K 38/45 (2006.01); A61K 47/48 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/3069 (2013.01); A61K 38/45 (2013.01); A61K 47/48569 (2013.01); A61K 47/48638 (2013.01); C07K 16/30 (2013.01); C07K 16/303 (2013.01); G01N 33/57423 (2013.01); G01N 33/57438 (2013.01); G01N 33/57449 (2013.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C12Y 204/02036 (2013.01); G01N 2333/705 (2013.01); G01N 2458/00 (2013.01);
Abstract

Described herein is the identification of a panel of high affinity monoclonal antibodies that bind GPC3. The disclosed antibodies recognize native GPC3 on the surface of cancer cells, as well as soluble GPC3. The highest affinity antibody (YP7) was further characterized and shown to be highly sensitive in that it was capable of detecting cancer cells with low expression of GPC3. YP7 also exhibited significant HCC tumor growth inhibition in vivo. Immunotoxins comprising the antibodies disclosed herein fused to PE38 exhibited very high binding affinity for GPC3-expressing cells and significantly inhibited GPC3-expressing cancer cell growth. Thus, the high-affinity monoclonal antibodies disclosed herein can be used for the diagnosis and treatment of GPC3-expressing cancers.


Find Patent Forward Citations

Loading…